Truist Financial Keeps Buy Rating on Amneal Pharmaceuticals with $8 PT

Truist Financial maintains a Buy rating on Amneal Pharmaceuticals (AMRX) with an $8 price target. The company's preliminary Q2 financial results show a 3% increase in net revenue to $720-$730 million and a 13% rise in adjusted EBITDA to $180-$185 million. Amneal Pharmaceuticals is a medicine company with a product portfolio that includes biosciences, specialty, generics, and product catalog.